← All companies ← BILL Manual BIOA → ← AVTR Life Sciences Tools & Services BLLN →
BIO, Bio-Rad
Bio-Rad is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables.
We have direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution.
Segments Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics.
The business
What it sells, where the money comes from, the kind of company it is.
Next report Est. 8/3 · the 10-Q for the quarter ended late June · due within 40 days of period end · has filed ~31 days after · the wire records it on arrival
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- What it is
- Revenue is Clinical Diagnostics (60%) and Life Science (40%).
- Situation
- Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
- What moves the needle
- Gross margin has run about 55% and operating margin about 10% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from −4.5% to 17% — on a steadier 55% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. Inventory runs near 26% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the installed base and the upgrade cycle. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median 3%, above 15% in 0 of 7 years). By owner earnings: roughly 10% of revenue reaches owners as cash, consistently. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 10-K →Clinical Diagnostics is 60% of revenue, with Life Science the other meaningful segment at 40%.
- Clinical Diagnostics60%$1.6B
- Life Science40%$1.0B
- All Other0%$0
From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMMar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $2.1B | $2.2B | $2.3B | $2.3B | $2.5B | $2.9B | $2.8B | $2.7B | $2.6B | $2.6B | $2.6B | RevenueRevenue |
| $1.1B | $1.2B | $1.2B | $1.3B | $1.4B | $1.6B | $1.6B | $1.4B | $1.4B | $1.3B | $1.3B | Gross profitGross prof. |
| 55% | 55% | 53% | 54% | 56% | 56% | 56% | 53% | 54% | 52% | 52% | Gross marginGross mgn |
| 39% | 37% | 36% | 36% | 31% | 30% | 30% | 32% | 32% | 33% | 33% | SG&A / revenueSG&A/rev |
| 10% | 12% | 9% | 9% | 9% | 9% | 9% | 9% | 12% | 11% | 10% | R&D / revenueR&D/rev |
| $56M | $119M | ($103M) | $230M | $421M | $500M | $483M | $338M | $269M | $47M | $58M | Operating incomeOp. inc. |
| 2.7% | 5.5% | −4.5% | 9.9% | 16.6% | 17.1% | 17.2% | 12.6% | 10.5% | 1.8% | 2.2% | Operating marginOp. mgn |
| $42M | $98M | $513M | $2.3B | $4.9B | $5.4B | ($4.7B) | ($850M) | ($2.3B) | $996M | — | Pretax incomePretax |
| $26M | $122M | $366M | $1.8B | $3.8B | $4.3B | ($3.6B) | ($637M) | ($1.8B) | $760M | $169M | Net incomeNet inc. |
| 37% | — | 29% | 22% | 22% | 22% | — | — | — | 24% | 24% | Effective tax rateTax rate |
| Cash flow & returns | |||||||||||
| $216M | $104M | $285M | $458M | $585M | $669M | $194M | $375M | $455M | $532M | $510M | Operating cash flowOp. cash |
| $143M | $149M | $138M | $134M | $139M | $138M | $137M | $146M | $152M | $165M | $165M | DepreciationDeprec. |
| $27M | ($190M) | ($246M) | ($1.5B) | ($3.4B) | ($3.8B) | $3.6B | $805M | $2.1B | ($451M) | $119M | Working capital & otherWC & other |
| $141M | $111M | $130M | $99M | $109M | $134M | $113M | $157M | $166M | $158M | $153M | CapexCapex |
| 6.8% | 5.2% | 5.7% | 4.3% | 4.3% | 4.6% | 4.0% | 5.9% | 6.5% | 6.1% | 5.9% | Capex / revenueCapex/rev |
| $75M | ($7M) | $156M | $359M | $476M | $536M | $82M | $218M | $290M | $375M | $357M | Owner earningsOwner earn. |
| 3.6% | −0.3% | 6.8% | 15.5% | 18.7% | 18.3% | 2.9% | 8.2% | 11.3% | 14.5% | 13.8% | Owner earnings marginOE mgn |
| $75M | ($7M) | $156M | $359M | $476M | $536M | $82M | $218M | $290M | $375M | $357M | Free cash flowFCF |
| 3.6% | −0.3% | 6.8% | 15.5% | 18.7% | 18.3% | 2.9% | 8.2% | 11.3% | 14.5% | 13.8% | Free cash flow marginFCF mgn |
| $0 | $3M | $49M | $28M | $100M | $50M | $216M | $429M | $204M | $296M | — | BuybacksBuybacks |
| ($214M) | ($176M) | ($187M) | ($209M) | ($70M) | ($797M) | ($1.2B) | $20M | ($160M) | ($190M) | — | Investing cash flowInv. cash |
| $9M | $341K | ($49M) | ($23M) | ($523M) | ($55M) | $974M | ($426M) | ($219M) | ($283M) | — | Financing cash flowFin. cash |
| ($13M) | ($1M) | ($655K) | $2M | $12M | ($13M) | $3M | $400K | $9M | ($17M) | — | Exchange-rate effectFX |
| ($1M) | ($72M) | $49M | $228M | $4M | ($196M) | ($37M) | ($30M) | $85M | $42M | — | Change in cashΔ cash |
| 1% | 4% | -2% | 3% | 4% | 3% | — | — | — | 0% | 1% | ROICROIC |
| 1% | 4% | 9% | 31% | 39% | 31% | -38% | -7% | -28% | 10% | 2% | Return on equityROE |
| 1% | 4% | 9% | 31% | 39% | 31% | −38% | −7% | −28% | 10% | 2% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $839M | $755M | $845M | $1.1B | $991M | $870M | $1.8B | $1.6B | $1.7B | $1.5B | $1.6B | Cash & investmentsCash+inv |
| $372M | $465M | $392M | $393M | $419M | $424M | $495M | $489M | $453M | $461M | $426M | ReceivablesReceiv. |
| $525M | $595M | $584M | $554M | $622M | $572M | $719M | $781M | $760M | $741M | $771M | InventoryInvent. |
| $133M | $135M | $122M | $107M | $139M | $142M | $135M | $145M | $122M | $129M | $133M | Accounts payablePayables |
| $764M | $924M | $854M | $840M | $902M | $854M | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | Operating working capitalOper. WC |
| $1.8B | $2.0B | $2.0B | $2.2B | $2.1B | $2.0B | $3.2B | $3.0B | $3.0B | $2.9B | $2.9B | Current assetsCur. assets |
| $471M | $503M | $451M | $905M | $632M | $681M | $569M | $523M | $468M | $517M | $917M | Current liabilitiesCur. liab. |
| 3.9× | 3.9× | 4.5× | 2.4× | 3.4× | 2.9× | 5.6× | 5.8× | 6.5× | 5.6× | 3.2× | Current ratioCurr. ratio |
| $489M | $493M | $509M | $499M | $491M | $512M | $499M | $529M | $528M | $540M | — | Net PP&ENet PP&E |
| $477M | $506M | $220M | $264M | $292M | $347M | $407M | $414M | $411M | $580M | $577M | GoodwillGoodwill |
| $3.9B | $4.3B | $5.6B | $8.0B | $13.0B | $17.8B | $13.5B | $12.3B | $9.4B | $10.6B | $9.8B | Total assetsAssets |
| $435M | $435M | $439M | $440M | $14M | $11M | $1.2B | $1.2B | $1.2B | $1.2B | $1.2B | Total debtDebt |
| ($405M) | ($320M) | ($405M) | ($675M) | ($977M) | ($859M) | ($593M) | ($408M) | ($464M) | ($331M) | ($355M) | Net debt / (cash)Net debt |
| 2.4× | 5.2× | -4.3× | 9.8× | 19.3× | 322.6× | 12.7× | 6.8× | 5.5× | 1.0× | 1.2× | Interest coverageInt. cov. |
| $1.3B | $1.3B | $1.6B | $2.3B | $3.1B | $4.1B | $3.9B | $3.6B | $2.8B | $3.1B | — | Total liabilitiesTotal liab. |
| $2.6B | $2.9B | $4.0B | $5.8B | $9.9B | $13.7B | $9.6B | $8.7B | $6.6B | $7.5B | $6.9B | Shareholders’ equityEquity |
| 1.0% | 1.1% | 1.2% | 1.5% | 1.6% | 1.8% | 2.2% | 2.3% | 2.4% | 2.2% | 2.2% | Stock comp / revenueSBC/rev |
| $14M | $12M | $282M | — | — | — | — | — | — | — | — | Goodwill written downGW imp. |
| Per share | |||||||||||
| 29.6M | 30.0M | 30.2M | 30.2M | 30.2M | 30.2M | 29.8M | 29.2M | 28.2M | 27.3M | 27.0M | Shares out (diluted)Shares |
| $69.76 | $71.92 | $75.74 | $76.59 | $84.40 | $96.75 | $94.08 | $91.45 | $90.97 | $94.69 | $96.07 | Revenue / shareRev/sh |
| $0.88 | $4.07 | $12.10 | $58.27 | $126.47 | $140.83 | $-121.79 | $-21.82 | $-65.36 | $27.85 | $6.26 | EPS (diluted)EPS |
| $2.52 | $-0.24 | $5.15 | $11.91 | $15.80 | $17.73 | $2.74 | $7.47 | $10.26 | $13.73 | $13.25 | Owner earnings / shareOE/sh |
| $2.52 | $-0.24 | $5.15 | $11.91 | $15.80 | $17.73 | $2.74 | $7.47 | $10.26 | $13.73 | $13.25 | Free cash flow / shareFCF/sh |
| $4.77 | $3.71 | $4.29 | $3.26 | $3.60 | $4.43 | $3.79 | $5.36 | $5.87 | $5.78 | $5.68 | Cap. spending / shareCapex/sh |
| $87.00 | $97.56 | $133.00 | $190.72 | $327.91 | $453.03 | $322.82 | $299.26 | $232.84 | $273.22 | $254.15 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +3.5%/yr | +2.3%/yr |
| Owner earnings / share | +20.7%/yr | −2.8%/yr |
| EPS | +46.9%/yr | −26.1%/yr |
| Capital spending / share | +2.1%/yr | +9.9%/yr |
| Book value / share | +13.6%/yr | −3.6%/yr |
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business reported $760M of profit but $375M of owner earnings: $385M less than the profit line, taken out by capital spending and the timing of cash.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | $760M | ($1.8B) | ($637M) | ($3.6B) | $4.3B |
| Depreciation & amortizationnon-cash charge added back | +$165M | +$152M | +$146M | +$137M | +$138M |
| Stock-based compensationreal costnon-cash, but a real cost | +$58M | +$62M | +$61M | +$61M | +$51M |
| Working capital & othertiming of cash in and out, other non-cash items | −$451M | +$2.1B | +$805M | +$3.6B | −$3.8B |
| Cash from operations | $532M | $455M | $375M | $194M | $669M |
| Capital expenditurecash put back in to keep running and to grow | −$158M | −$166M | −$157M | −$113M | −$134M |
| Owner earnings | $375M | $290M | $218M | $82M | $536M |
| Owner-earnings marginowner earnings ÷ revenue | 15% | 11% | 8% | 3% | 18% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $58M), owner earnings is nearer $317M.
Much of fiscal 2025's profit didn't arrive as operating cash; it sits in “working capital & other” above. That can be a real inventory or timing swing, or profit that doesn't run through operating cash at all: a heavy tax year, equity-method earnings, or investment income booked through investing. For a year like this, owner earnings understates the cash earned; the full cash-flow statement carries the rest.
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Does not cover its interestOperating income $47M ÷ interest expense $49M
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net cashCash $530M + ST investments $1.0B − debt $1.2B
What this means
Cash and short-term investments exceed every dollar of debt by $331M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 65 + DIO 217 − DPO 38 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle7-yr median, range -2%–4%; 0% latest = NOPAT $36M ÷ invested capital $8.1BIndustry peers: median 17%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 7 years (it ran 0% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Solid through the cycle10-yr median margin, range -0%–19%; latest $375M = operating cash $532M − maintenance capex $158MIndustry peers: median 18%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 15% of revenue this year, a 10% median across 10 years. Treating stock comp as the real expense it is (less $58M of SBC) leaves $317M.
- Mostly cash-backedCash from ops $532M ÷ net income $760M
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Returns about halfDividends + buybacks $296M ÷ Owner Earnings $375M — this fiscal year
What this means
Of $375M Owner Earnings, $296M (79%) went back to shareholders, $0 dividends, $296M buybacks. Net of $58M stock comp, the real buyback was about $238M. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does. This year's proportion is 79%; across the record (2016–2025) it is 54%, the capital-allocation section below.
- Investing or harvesting? 0.95×MaintainingCapex $158M ÷ depreciation $165M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
The promise and the pay packet
- Is the buyback buying ownership, or mopping up? 2.2%The count is genuinely shrinkingStock compensation $58M (fiscal 2025), 2.2% of revenue · repurchases $296M · diluted shares -8.4% since 2022
What this means
Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.
Graham’s defensive tests · 3 of 5 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size PassRevenue ≥ $2B · $2.6B
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 5.62×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt PassDebt ≤ working capital · $1.2B vs $2.4B WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 3 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record —Uninterrupted dividends · no dividend line tagged in the data
What this means
An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.
- Earnings growth MissEarnings +33% over the record · −435%
What this means
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-21.29/share (latest year $28.19), the averaged base the calculator's gate runs on, and book value is $276.49/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 7 of 10
What this means
Lost money in 3 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 0 of 10 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 1% → 8% (3-yr avg ends)
What this means
Through the cycle the operating margin widened — about 1% early to 8% lately, median 10% — pricing power intact or improving.
- Reinvestment, incremental ROIC 3%
What this means
Reinvested capital came back at only a modest incremental return — near the cost of capital, where extra growth adds little per dollar. The record shows whether it is a soft stretch or a thinning moat.
- Owner earnings growth +29%/yr
What this means
Owner earnings grew about 29% a year over the record.
- Worst year 2018 · −4.5% op. margin
What this means
Operations went underwater in 2018, understand why before trusting the good years.
- Share count −0.9%/yr
What this means
The share count is shrinking, buybacks are quietly growing your slice of the business.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Mar 31, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$1.6B
- Receivables$426M
- Inventory$771M
- Other current assets$181M
- Debt due within a year$200K
- Accounts payable$133M
- Other current liabilities$784M
From the company's latest filing.
How the cash was used, 2016–2025
Over the record, the business generated $3.9B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.
- Reinvested$1.3B · 34%
- Buybacks$1.4B · 35%
- Retained (debt / cash)$1.2B · 31%
- Returned to owners$1.4B
54% of the owner earnings the business produced over the span, $0 as dividends and $1.4B as buybacks.
- Source of fundingOperating cash
Operating cash covered reinvestment and returns; over the span debt rose $776M and cash and short-term investments rose $725M.
- Average price paid for buybacks—
Buybacks ran $1.4B over the span, but the filings don't tag the share count needed to deduce the average price paid.
- Net change in share count−9.1%
The diluted count fell from 30M to 27M, so the buybacks outran the stock issued to staff.
- Dividend record—
No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.
- Return on what it retained6%
Of the earnings it kept rather than paid out ($3.6B over the span), annual owner earnings (first three years vs last three) grew $220M, so each retained $1 added about 0.06 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.
| Fiscal year | Chief executive | Pay, as filed | “Actually paid” | Owner earnings |
|---|---|---|---|---|
| 2021 | Norman Schwartz | $8.7M | $20.4M | $536M |
| 2022 | Norman Schwartz | $7.5M | −$5.6M | $82M |
| 2023 | Norman Schwartz | $7.5M | $1.0M | $218M |
| 2024 | Norman Schwartz | $8.3M | $8.6M | $290M |
| 2025 | Norman Schwartz | $8.0M | $7.3M | $375M |
Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.
- Insider ownership14.8%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- Stock-based compensation$58M
The slice of the business handed to employees in shares in fiscal 2025, 2.2% of revenue, equal to 122.9% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
Peers, Life Sciences Tools & Services
The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| AAgilent Technologies Inc. | $6.9B | 54% | 19.1% | 17% | 18% |
| AVTRAvantor Inc. | $6.6B | 34% | 10.0% | 7% | 9% |
| ILMNIllumina Inc. | $4.3B | 67% | 18.2% | 16% | 23% |
| MTDMettler-Toledo International Inc. | $4.0B | 58% | 26.1% | 43% | 21% |
| BRKRBruker | $3.4B | 48% | 13.2% | 18% | 7% |
| WATWaters Corporation | $3.2B | 59% | 28.8% | 28% | 18%3y |
| RVTYRevvity Inc. | $2.9B | 48% | 12.8% | 4% | 16% |
| BIOBio-Rad | $2.6B | 55% | 10.2% | 3% | 10% |
| Group median | — | 54% | 15.7% | 17% | 17% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Bio-Rad has delivered.
Bio-Rad’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Bio-Rad earns about $251M on its 9.7% median owner-earnings margin. This year’s 14.5% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.
—
9.0% = the 4.68% 10-year Treasury (Jul 30, 2026) + 4.32 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.68%, as of Jul 30, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings $357M on 27M shares outstanding (a weighted basic average, the only count this filer tags); net cash $355M. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← BILL its page in the Manual BIOA →
Industry order: ← AVTR the Life Sciences Tools & Services chapter BLLN →